AVLN - Company ID 0001540171
The table below shows Avalyn Pharma Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of revenue | - | - | - | - |
| Gross profit | - | - | - | - |
| R&D | $24.73M | $22.89M | $17.88M | $15.32M |
| SG&A | $6.56M | $5.02M | $3.90M | $3.40M |
| Operating income | -$31.29M | -$27.91M | -$21.78M | -$18.72M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Income tax | - | $0.00 | - | $0.00 |
| Net income | -$28.93M | -$26.87M | -$20.19M | -$17.50M |
| EPS (diluted) | -$0.98 | -$21.83 | -$17.63 | -$63.24 |